Search
Pennsylvania Paid Clinical Trials
A listing of 3457 clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 24 of 3457
Pennsylvania is currently home to 3457 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Atopic Dermatitis (Eczema) Study
Recruiting
The purpose of this clinical study is to see whether an investigational injectable medication can help to treat symptoms of moderate to severe Atopic Dermatitis (eczema). You may qualify to participate if you were diagnosed with Atopic Dermatitis at least 1 year ago and are currently experiencing symptoms. Participants who qualify for the study will receive trial-related procedures and study medication at no cost. The site staff can provide you with additional details.
Conditions:
Atopic Dermatitis
Dermatitis
Atopic
Atopic Dermatitis Eczema
Atopic Eczema
* Compensation for time may be available
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2024
Locations: DermDox Centers for Dermatology, Camp Hill, Pennsylvania
Conditions: Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
REBYOTAâ„¢ Prospective Registry
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTAâ„¢ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTAâ„¢ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Ferring Investigational Site, DuBois, Pennsylvania
Conditions: Recurrence of Clostridium Difficile Infection
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
Recruiting
This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS. People who have previously taken specific medicines such as immunosuppressive biologics other than Tumor necrosis factor (TNF) inhibitors cannot take part.
This study has 2 parts. In Part 1, participants are divided into 4 groups of almost equal size. 3 groups get different doses of spesolimab, 1 group gets placeb... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hidradenitis Suppurativa
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Recruiting
Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to anti... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/15/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Crohn Disease
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Recruiting
The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in participants with moderate to severe rotator cuff tendinopathy (RCT), using a randomized, double-blind, placebo controlled, parallel group design to minimize bias.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2024
Locations: Altoona Center for Clin Res ., Duncansville, Pennsylvania
Conditions: Rotator Cuff Tendinopathy
Pain and Disability Outcomes in Post Amputation Patients
Recruiting
The objective of this study is to evaluate efficacy of varied medical and procedural therapies used to treat pain after surgical amputation of a limb. The primary outcome will be assessment of pain severity at rest and with movement as measured by pain scores on Numerical Rating Scale (NRS) 0 to 10, where 0 is not pain and 10 is the worst pain possible, taken on post-operative day 1, day 7, 30 days, 90 days, 6 months, and 1 year (+/- 3 days at each time point).
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
04/15/2024
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Limb Pain, Phantom, Residual Limbs Pain, Disability Physical
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
Recruiting
To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/15/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Alzheimer's Disease
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Local Institution - 0047, Hershey, Pennsylvania
Conditions: Cardiomyopathy, Hypertrophic
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
Recruiting
This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called diffuse cutaneous systemic sclerosis. People with another subtype called limited cutaneous systemic sclerosis can also participate if they are anti Scl-70 antibody positive. Systemic sclerosis is also called scleroderma.
The purpose of this study is to find out whether a medicine called Avenciguat (BI 685509) helps people with scleroderma w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Scleroderma, Systemic
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
Recruiting
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Pittsburgh MC, Pittsburgh, Pennsylvania
Conditions: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
COVID Booster in Pregnancy and Lactation
Recruiting
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
Gender:
Female
Ages:
Between 13 years and 55 years
Trial Updated:
04/15/2024
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: COVID-19